Use of camptothecin derivates for the treatment of proliferative diseases in a fixed dosing regimen

Details for Australian Patent Application No. 2005226932 (hide)

Owner Novartis AG

Inventors Schran, Horst F.; Woo, Margaret Ma

Agent Davies Collison Cave

Pub. Number AU-B-2005226932

PCT Pub. Number WO2005/092302

Priority 60/556,729 26.03.04 US

Filing date 24 March 2005

Wipo publication date 6 October 2005

Acceptance publication date 9 July 2009

International Classifications

A61K 31/4745 (2006.01)

A61K 31/00 (2006.01)

Event Publications

28 September 2006 PCT application entered the National Phase

  PCT publication WO2005/092302 Priority application(s): WO2005/092302

9 July 2009 Application Accepted

  Published as AU-B-2005226932

19 November 2009 Standard Patent Sealed

21 October 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This patent ceased under section 143(a), or Expired. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2005226938-Format selecting device for wiping material dispensing arrangement

2005226928-Novel use of peptide compounds for treating pain in painful diabetic neuropathy